Impact & Utility of a Global Registry Infrastructure for Device Evidence: ESC Regulatory Affairs Committee Perspective

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:

• Grant Support/Research Contract - Abbott; Abiomed; Amgen; AstraZenca; Bayer AG; Bbraun; Biotronik; Boehringer Ingelheim; Boston Scientific Corporation; Bristol-Myers Squibb; Cardinal Health; CardioValve; Cleerly Inc.; Cordis Corporation, a Johnson & Johnson company; Corflow Therapeutics; CSL Behring; Daiichi-Sankyo/Elil Lilly and Company; Edwards Lifesciences; Farapulse Inc.; Fumedica; GE Healthcare; Gebro Pharma; Guerbet; Idorsia; Inari Medical; InfraredX; Janssen Pharmaceuticals; Johnson&Johnson; Medalliance; Medicure; Medtronic; Merck Sharp&Dohm; Miracor Medical; Neucomed; Novartis; Novo Nordisk; Organon; Orpha Suisse; Pharming Tech; Pfizer; Philips; Polares; Regeneron; Sanofi Aventis; Servier; Siemens Healthcare; Sinomed; SMT; Sahaianand Medical Technologies; Terumo Medical Corporation; Vifor; V-Wave; Zoll